VIDEO: Targeting mutant calreticulin in myeloproliferative neoplasms

ByAnn Mullally, MD

ByMarley V. Ghizzone

Fact checked byMindy Valcarcel, MS

In this video, Ann Mullally, MD, discussed her presentation investigating the use of therapeutic antibodies to target mutant calreticulin in myeloproliferative neoplasms.

The data was presented at 14th International Congress on Myeloproliferative Neoplasms.

“Calreticulin, I believe, is a really important and exciting therapeutic target in myeloproliferative neoplasms,” Mullally, associate professor of medicine at Harvard Medical School, physician-scientist at Brigham and Women’s Hospital and Dana-Farber Cancer Institute, and associate member at Broad Institute, said. “Because of the nature of the calreticulin mutations, we’re hopeful it will be possible to target this mutant protein with antibodies.”

Reference:

Mullally A. Pursuing monoclonal antibodies for MPNS: targeting mutant calreticulin. Presented at: 14th International Congress on Myeloproliferative Neoplasms; Oct. 27-28, 2022; Brooklyn, New York.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interviews

Disclosures: Healio was unable to determine relevant financial disclosures at the time of publication.

Discoveries in Myeloproliferative Neoplasms

Read more

VIDEO: Targeting mutant calreticulin in myeloproliferative neoplasms

Reference:

Related Content